What was the market valuation of the human growth-hormone market in 2024?

The market valuation was $172.5 Million in 2024. Read More

What is the projected market valuation for the human growth-hormone market by 2035?

The projected valuation for 2035 is $561.17 Million. Read More

What is the expected CAGR for the human growth-hormone market during the forecast period 2025 - 2035?

The expected CAGR is 11.32% during the forecast period 2025 - 2035. Read More

Which companies are considered key players in the human growth-hormone market?

Key players include Pfizer Inc, Eli Lilly and Company, Merck KGaA, Novartis AG, and others. Read More

What are the leading brands in the human growth-hormone market and their valuations?

Leading brands include Genotropin at $40.0 - $150.0 Million and Norditropin at $30.0 - $100.0 Million. Read More

What routes of administration are prevalent in the human growth-hormone market?

Subcutaneous administration leads with a valuation of $60.75 - $197.5 Million. Read More

What applications are driving the human growth-hormone market?

Pediatric Growth Hormone Deficiency is a major application, valued at $34.5 - $115.0 Million. Read More

How is the distribution channel structured in the human growth-hormone market?

Retail pharmacies account for a significant share, with a valuation of $51.75 - $170.0 Million. Read More

What is the valuation range for the brand Humatrope in the human growth-hormone market?

Humatrope has a valuation range of $25.0 - $80.0 Million. Read More

What is the market outlook for the human growth-hormone market in South Korea?

The market outlook appears positive, with a projected growth to $561.17 Million by 2035. Read More

South Korea Human Growth Hormone Market

South Korea Human Growth Hormone Market Research Report By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, Others), By Route of Administration (Subcutaneous, Intramuscular, Intravenous), By Application (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Specialty Pharmacy) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

11.32%

2024 Market Size

$ 172.5 Million

2035 Market Size

$ 561.17 Million

Healthcare ● Updated August 2026 Report ID: MRFR/HC/43243-HCR | Pages: 200 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Brand (USD Million)
  1. 4.1.1 Norditropin
  2. 4.1.2 Genotropin
  3. 4.1.3 Humatrope
  4. 4.1.4 Saizen
  5. 4.1.5 Omnitrope
  6. 4.1.6 Skytrofa
  7. 4.1.7 Others
2. 4.2 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.2.1 Subcutaneous
  2. 4.2.2 Intramuscular
  3. 4.2.3 Intravenous
3. 4.3 Chemicals and Materials, BY Application (USD Million)
  1. 4.3.1 Pediatric Growth Hormone Deficiency
  2. 4.3.2 Adult Growth Hormone Deficiency
  3. 4.3.3 Idiopathic Growth Hormone Deficiency
  4. 4.3.4 Small for Gestational Age
  5. 4.3.5 Turner Syndrome
  6. 4.3.6 Prader-Willi Syndrome
  7. 4.3.7 Others
4. 4.4 Chemicals and Materials, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacy
  4. 4.4.4 Specialty Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly and Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck KGaA (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim GmbH (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Ferring Pharmaceuticals (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ipsen S.A. (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sandoz International GmbH (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Hikma Pharmaceuticals PLC (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH KOREA MARKET ANALYSIS BY BRAND
3. 6.3 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
5. 6.5 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY BRAND, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY BRAND, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY BRAND, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South Korea South Korea Human Growth Hormone Market Segmentation

South Korea Human Growth Hormone Market By Brand (USD Million, 2025-2035)

Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Skytrofa
Others

South Korea Human Growth Hormone Market By Route of Administration (USD Million, 2025-2035)

Subcutaneous
Intramuscular
Intravenous

South Korea Human Growth Hormone Market By Application (USD Million, 2025-2035)

Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Idiopathic Growth Hormone Deficiency
Small for Gestational Age
Turner Syndrome
Prader-Willi Syndrome
Others

South Korea Human Growth Hormone Market By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacy
Specialty Pharmacy

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”